InVivo Biosystems has partnered with BioReperia to accelerate cancer drug discovery. With the ZTX® xenograft, oncologic therapeutic efficacy testing is reduced from 6+ months to 5 days.
One Oncology Platform, Multiple Purposes
The ZTX® platform serves the pharmaceutical industry in both preclinical development and precision medicine. The zebrafish xenografts may be used independently for rapid evaluation of immuno-therapies, or used as a companion tool in CDX or PDX modeling.
ZTX® Xenograft Highlights
- Evaluation of immuno-therapies: The ZTX® platform is being used to evaluate efficacy of T-cell and other immune cell cytotoxicity activating drugs including checkpoint inhibitors and autologous therpies within immune-oncology.
- Fast-tracked CDX and PDX modeling: The solid microtumor cells formed within the zebrafish embryos are cultured using CDX or PDX models, and even primary tumors from patients. More than 80 PDX models have been validated using the ZTX® platform.
- Human immune cell hosting: The platform effectively hosts human immune cells without any alterations, making it a powerful tool for exploring any immune-oncology resarch requiring validation.
- Applicable to all compound types: Small molecules, large peptides, antibodies, ADCs, and nanoparticles may be tested for efficacy.
The Zebrafish Oncology Solution
The ZTX® platform is a tool for both accelerated drug discovery and personalized medicine. The zebrafish model is used to produce oncologic xenografts which are then used in PDX, CDX, and primary patient tumors to discover and validate oncologic treatment outcomes.
Zebrafish as an Oncology Model
The fast development of the zebrafish embryo enables rapid vascularization of a developed microtumor. The solid microtumor becomes vascularized and a tumor microenvironment can be reconstituted within 3 days, both of which allow metastasis invasion.
Validation of Therapeutic Outcome at Record Speed
The ZTX® platform is a reliable companion diagnostic tool to use in CDX and PDX studies. The platform has a 79% treatment correlation to traditional PDX therapeutic outcome, while cutting up to 98% of the average validation study time.
Learn More About the ZTX® Platform
Stay On the Cutting Edge with InVivo Biosystems Blogs
Humanized Models: Shaping the Future of Drug Discovery and Development
Humanized C. elegans Models for Epilepsy Drug Development
Elevating Target Identification and Validation with MIC-Drop™: The Power of Multiplexed CRISPR in Preclinical Development
Eugene, Oregon: The Epicenter of Zebrafish Research
Press Release: InVivo Biosystems Announces Groundbreaking Innovation in Preclinical Development
